Aktis Oncology is a biotechnology company focused on transforming cancer care with novel platform technologies that enable the design and development of precision radiopharmaceuticals. These targeted therapies harness the potent anticancer effects of alpha-emitting particles. The company is pursuing a broad set of targets in commonly occurring cancers to create radiopharmaceuticals that could provide treatment options where currently limited therapies exist.